We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-14.02%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$270M
AUM Growth
+$46.4M
(+21%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
32.16%
Top 10 Holdings %
Top 10 Hldgs %
7.48%
Holding
501
New
128
Increased
202
Reduced
102
Closed
67
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Realty Income
O
|
+$931K |
| 2 |
SK Telecom
SKM
|
+$871K |
| 3 |
Moderna
MRNA
|
+$825K |
| 4 |
ConocoPhillips
COP
|
+$786K |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$785K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agnico Eagle Mines
AEM
|
+$1.83M |
| 2 |
BPMP
BP Midstream Partners LP Common Units representing Limited Partner Interests
BPMP
|
+$1.76M |
| 3 |
The Mosaic Company
MOS
|
+$928K |
| 4 |
STR
Sitio Royalties
STR
|
+$559K |
| 5 |
Gold Fields
GFI
|
+$512K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.55% |
| 2 | Healthcare | 17.07% |
| 3 | Materials | 11.98% |
| 4 | Financials | 11.43% |
| 5 | Energy | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Celldex Therapeutics
CLDX
$2.8B
| $130K | 0.05% |
4,816
+685
| +17% | +$19.9K |
|
|
SGMO
352
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $130K | 0.05% |
31,424
+10,441
| +50% | +$45.2K |
|
353
ImmunityBio
IBRX
$7.32B
| $129K | 0.05% |
34,799
+7,456
| +27% | +$29.9K |
|
|
NBP
354
NovaBridge Biosciences American Depositary Shares
NBP
$206M
| $129K | 0.05% |
11,446
+8,310
| +265% | +$99.6K |
|
355
Invivyd
IVVD
$180M
| $129K | 0.05% |
39,281
+17,926
| +84% | +$56.2K |
|
356
Regenxbio
RGNX
$622M
| $129K | 0.05% |
5,209
+379
| +8% | +$9.47K |
|
|
VXRT
357
DELISTED
Vaxart
VXRT
| $129K | 0.05% |
36,904
+11,521
| +45% | +$43K |
|
358
Vaxcyte
PCVX
$8.01B
| $128K | 0.05% |
+5,865
| New | +$136K |
|
|
RNAM
359
DELISTED
Avidity Biosciences
RNAM
| $128K | 0.05% |
8,781
+2,495
| +40% | +$37.1K |
|
|
EQRX
360
DELISTED
EQRx, Inc. Common Stock
EQRX
| $128K | 0.05% |
+27,289
| New | +$123K |
|
|
AFMD
361
DELISTED
Affimed
AFMD
| $127K | 0.05% |
4,568
+1,681
| +58% | +$57.5K |
|
362
ALX Oncology
ALXO
$272M
| $127K | 0.05% |
15,641
+9,176
| +142% | +$99.9K |
|
363
Arcturus Therapeutics
ARCT
$164M
| $127K | 0.05% |
8,039
+3,507
| +77% | +$68.8K |
|
|
RAPT
364
DELISTED
RAPT Therapeutics
RAPT
| $127K | 0.05% |
871
+236
| +37% | +$31.5K |
|
365
Arcus Biosciences
RCUS
$3.5B
| $127K | 0.05% |
5,029
+1,075
| +27% | +$26.3K |
|
366
Syndax Pharmaceuticals
SNDX
$1.82B
| $127K | 0.05% |
6,584
-2,139
| -25% | -$35.6K |
|
367
Geron
GERN
$949M
| $126K | 0.05% |
81,016
-40,127
| -33% | -$56.7K |
|
|
SWTX
368
DELISTED
SpringWorks Therapeutics
SWTX
| $126K | 0.05% |
5,111
+2,823
| +123% | +$103K |
|
369
AbCellera Biologics
ABCL
$1.6B
| $125K | 0.05% |
11,784
| – | – |
|
|
DVAX
370
DELISTED
Dynavax Technologies
DVAX
| $125K | 0.05% |
9,904
-1,688
| -15% | -$17.9K |
|
371
IDEAYA Biosciences
IDYA
$3.54B
| $125K | 0.05% |
9,088
+1,896
| +26% | +$21.1K |
|
372
Inovio Pharmaceuticals
INO
$79.4M
| $125K | 0.05% |
6,001
+3,814
| +174% | +$107K |
|
373
Prelude Therapeutics
PRLD
$310M
| $125K | 0.05% |
24,005
+10,957
| +84% | +$55.8K |
|
374
Relay Therapeutics
RLAY
$4.06B
| $125K | 0.05% |
7,476
+1,918
| +35% | +$41.1K |
|
375
Replimune Group
REPL
$724M
| $124K | 0.05% |
7,108
+1,461
| +26% | +$24K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, Virtus ETF Advisers held 501 positions worth $270M, up 21% from $223M the previous quarter. Its ten largest holdings account for 7.5% of the portfolio.
Virtus ETF Advisers deployed $86.8M of net new capital in Q2 2022, opening 128 new positions and adding to 202 existing holdings. Its largest new stake was ConocoPhillips: 7,627 shares worth $685K.
By sector, the portfolio is most concentrated in Real Estate at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Materials.
On the sell side, the largest reduction was Agnico Eagle Mines, an estimated $1.83M trimmed.
- Virtus ETF Advisers's largest Q2 2022 buy was ConocoPhillips: 7,627 shares worth $685K.
- Virtus ETF Advisers added most to Realty Income in Q2 2022, an estimated $931K increase.
- Virtus ETF Advisers's biggest Q2 2022 reduction was Agnico Eagle Mines, cutting an estimated $1.83M.
- Virtus ETF Advisers fully exited BP Midstream Partners LP Common Units representing Limited Partner Interests in Q2 2022, selling an estimated $1.76M.
- Virtus ETF Advisers's ten largest holdings make up 7.5% of its $270M portfolio in Q2 2022.
- Virtus ETF Advisers opened 128 new positions and closed 67 in Q2 2022.
- Virtus ETF Advisers's portfolio value rose 21% quarter-over-quarter to $270M.
Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.